Cyrus Harmon Sells 12,500 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Posted by Brenda Bartman on Jul 28th, 2026

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) Director Cyrus Harmon sold 12,500 shares of the company’s stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the transaction, the director directly owned 715,270 shares in the company, valued at approximately $8,282,826.60. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock traded down $0.71 during trading on Tuesday, hitting $11.30. The company had a trading volume of 377,119 shares, compared to its average volume of 1,468,464. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. Olema Pharmaceuticals, Inc. has a one year low of $4.47 and a one year high of $36.26. The firm has a market capitalization of $987.11 million, a P/E ratio of -5.60 and a beta of 2.00. The stock’s 50-day moving average price is $11.59 and its 200 day moving average price is $16.90.

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). Equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on OLMA. HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Friday, May 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen cut Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Guggenheim lowered their price target on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Olema Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $44.10.

Get Our Latest Stock Analysis on Olema Pharmaceuticals

Institutional Investors Weigh In On Olema Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Siren L.L.C. purchased a new stake in Olema Pharmaceuticals in the fourth quarter worth $82,518,000. Janus Henderson Group PLC grew its holdings in Olema Pharmaceuticals by 87.1% during the 4th quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock worth $167,901,000 after acquiring an additional 3,124,345 shares in the last quarter. Cormorant Asset Management LP purchased a new position in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $68,750,000. RA Capital Management L.P. acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth $65,000,000. Finally, Bain Capital Life Sciences Investors LLC boosted its holdings in Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after purchasing an additional 1,664,687 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

About Olema Pharmaceuticals

(Get Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.